Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855459 · ClinicalTrials.gov registry record · NA

The Impact of Biophoton Therapy on Self-Grown Stem Cells

A NA study of Inflammation and Increase the Total Number of Stem Cells, sponsored by First Institute of All Medicines.

Recruiting
Registry status
NA
Development phase
46
Enrollment target
2
Study locations

NCT06855459: Recruiting NA study of Inflammation and Increase the Total Number of Stem Cells, sponsored by First Institute of All Medicines.

NCT06855459 is a NA study of Inflammation and Increase the Total Number of Stem Cells that is actively recruiting participants, run by First Institute of All Medicines. The registered enrollment target is 46 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855459, a NA study of Inflammation and Increase the Total Number of Stem Cells, is actively recruiting participants, sponsored by First Institute of All Medicines.

RECRUITING
Registry status
NA
Development phase
46 participants
Enrollment target
2
Study locations

Study Summary

Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.

Primary Outcome

To determine if treatment with Biophoton Generator can impact self-grown steam cells naturally

Interventions

  • DEVICE Biophoton Generators

Study Locations (2)

Florida

  • Tesla MedBed at Tampa-FL - Tampa

Pennsylvania

  • Tesla BioHealing Wellness Hotel - Butler-PA - Butler

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2025-02-10
Est. Completion 2026-03-30
Phase NA
First Institute of All Medicines

6 total trials

What NCT06855459 shows while recruiting

NCT06855459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (84% lower).

The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Biophoton Generators is the first listed.

NCT06855459 reports a single indexed study location in Florida, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06855459 about?

NCT06855459 is a clinical study titled "The Impact of Biophoton Therapy on Self-Grown Stem Cells". Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical stud...

What is the current status of trial NCT06855459?

This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2025-02-10. Estimated completion is 2026-03-30.

What conditions does trial NCT06855459 study?

This clinical trial studies the following conditions: Inflammation, Increase the Total Number of Stem Cells.

What interventions are being tested in trial NCT06855459?

The interventions under investigation include: Biophoton Generators (DEVICE).

Who is sponsoring clinical trial NCT06855459?

This trial is sponsored by First Institute of All Medicines, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855459 being conducted?

This trial has 2 study locations across Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06855459's enrollment target sits among peer trials

46 79th of 132 higher than 53 of 132 other Inflammation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06855459, the US trial registry maintained by the National Library of Medicine. NCT06855459 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.